在微质TNFα调节中Id2的新效应
Wenhui Wang1, Asiru1, Guoya Luo1
1Neurobiology Research Center, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, No. 66, Gongchang Road, Guangming District, Shenzhen, Guangdong, 518107, People's Republic of China.
Molecular neurobiology
|June 8, 2024
概括
抑制DNA结合蛋白2 (Id2) 的抑制剂在微质中负面调节炎症性细胞因子瘤坏死因子-α (TNFα). PDZ和LIM 5 (PDLIM5) 蛋白与Id2的相互作用促进TNFα的释放,从而导致神经炎症.
科学领域:
- 神经免疫学 神经免疫学
- 细胞和分子神经科学
背景情况:
- 微质是中枢神经系统 (CNS) 中的关键免疫细胞,对防御至关重要,但在失调时与神经炎症有关.
- 神经炎症是由微质细胞的过度炎症性细胞因子驱动的,是许多神经疾病的核心.
- 控制微质前炎性细胞因子产生的精确分子机制尚不完全理解.
研究的目的:
- 阐明DNA结合蛋白2 (Id2) 抑制剂在微质中调节促炎性细胞因子产生中的作用.
- 调查Id2,核因子kappa-B (NF-κB) 和瘤坏死因子-alpha (TNFα) 信号传导之间的相互作用.
- 确定参与微质激活和神经炎症的新型调节因素.
主要方法:
- 使用初级微细胞培养来评估Id2功能.
- 用基因操纵技术 (敲击和过度表达) 来研究Id2对TNFα表达的影响.
- 协同免疫沉和免疫染被用来研究蛋白质-蛋白质相互作用和亚细胞局部化.
- 对NF-κB转录活性进行了评估,以响应Id2调制.
主要成果:
- Id2被确定为微质中TNFα表达的负调节者.
- 打倒Id2增加了TNFα水平,而Id2过度表达抑制了它.
- Id2通过与NF-κB的p65亚单元相互作用来抑制TNFα转录.
- 脂聚糖 (LPS) 治疗诱导了Id2上调和细胞质转移.
- 支架蛋白PDZ和LIM 5 (PDLIM5) 与Id2结合,促进其细胞质转移和失活,导致LPS治疗的微质细胞中TNFα释放的增加.
结论:
- Id2 作为微质细胞中 TNFα 的关键负调节剂.
- Id2的PDLIM5介导的细胞质转移是一种激活TNFα生产的新机制.
- 这些发现提供了对微质炎症的分子控制和神经免疫疾病的潜在治疗点的见解.
相关概念视频
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130


